Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.43 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10563358 | 0.82 | ALOX15 (0.55) | CYP3A4ALDH1A1SMN1; SMN2MAPK1ALOX15 | |
| SCHEMBL6092940 | 0.82 | ESR1 (0.55) | ALDH1A1SMN1; SMN2ALOX15ALOX12KDM4E | |
| SCHEMBL23222948 | 0.78 | ALDH1A1 (0.54) | CYP3A4ALDH1A1SMN1; SMN2MAPK1ABCB1 | |
| SCHEMBL2070801 | 0.77 | CYP3A4 (0.43) | CYP3A4ALDH1A1SMN1; SMN2MAPK1ABCB1 | |
| SCHEMBL10561540 | 0.76 | ALOX15 (0.66) | CYP3A4ALOX15ALOX12ESR1ESR2 | |
| SCHEMBL11634581 | 0.74 | ALDH1A1 (0.55) | CYP3A4ALDH1A1SMN1; SMN2MAPK1ABCB1 | |
| SCHEMBL14338687 | 0.74 | ALOX15 (0.46) | CYP3A4ALDH1A1SMN1; SMN2MAPK1ALOX15 | |
| SCHEMBL11050278 | 0.73 | ALDH1A1 (0.52) | CYP3A4ALDH1A1SMN1; SMN2MAPK1ABCB1 | |
| SCHEMBL17558551 | 0.73 | ABCB1 (0.73) | CYP3A4ALDH1A1SMN1; SMN2MAPK1ABCB1 | |
| SCHEMBL9101407 | 0.73 | ABCB1 (0.73) | CYP3A4ALDH1A1SMN1; SMN2MAPK1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-7488494-B2 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-02-10 | — | — | US | disclosed |
| US-7488494-B2 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-02-10 | — | — | US | disclosed |
| US-7488494-B2 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-02-10 | — | — | US | disclosed |
| US-20080014249-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. | 2008-01-17 | — | — | US | disclosed |
| US-20080014249-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. | 2008-01-17 | — | — | US | disclosed |
| US-20080014249-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. | 2008-01-17 | — | — | US | disclosed |
| EP-1721903-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | Novogen Research Pty. Ltd. (AU) | 2006-11-15 | — | — | EP | disclosed |
| US-20060106220-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY. LTD. | 2006-05-18 | — | — | US | disclosed |
| US-20040147551-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | NOVOGEN RESEARCH PTY LTD. | 2004-07-29 | — | — | US | disclosed |
| EP-1210341-A4 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RES PTY LTD (AU) | 2003-06-11 | — | — | EP | disclosed |
| EP-1210341-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | Novogen Research Pty. Ltd. (AU) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001017986-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106220-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | SHBG, OAT, APOB | CYP3A4 2407/4885ALDH1A1 3385/4885SMN1; SMN2 1044/4885 |
| US-20080014249-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | SHBG, ESR2, GPER1 | CYP3A4 676/4885ALDH1A1 2374/4885SMN1; SMN2 3439/4885 |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | SHBG, OAT, APOB | CYP3A4 2407/4885ALDH1A1 3385/4885SMN1; SMN2 1044/4885 |
| US-20040147551-A1 | Compositions and therapeutic methods involving isoflavones and analogues thereof | SHBG, ESR2, GPER1 | CYP3A4 486/4885ALDH1A1 2034/4885SMN1; SMN2 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.